Published in J Steroid Biochem on May 01, 1989
Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol (2008) 2.35
Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene (2013) 1.86
Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab (2008) 1.78
Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res (2009) 1.32
Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer (2011) 1.28
Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol (2009) 1.26
Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med (2011) 1.24
5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate (2010) 1.15
Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol (2009) 1.14
The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am (2011) 1.13
Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol (2011) 1.06
Targeting 5α-reductase for prostate cancer prevention and treatment. Nat Rev Urol (2011) 1.06
Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells. J Steroid Biochem Mol Biol (2008) 0.99
High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients. BMC Cancer (2014) 0.83
Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer. PLoS One (2012) 0.82
Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors. Prostate (2013) 0.82
New developments in the treatment of castration resistant prostate cancer. Asian J Androl (2014) 0.81
Non-invasive measurement of adrenocortical and gonadal activity in male and female guinea pigs (Cavia aperea f. porcellus). Gen Comp Endocrinol (2008) 0.80
An aptameric graphene nanosensor for label-free detection of small-molecule biomarkers. Biosens Bioelectron (2015) 0.79
The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer. Horm Cancer (2016) 0.78
Regulation of 3β-hydroxysteroid dehydrogenase/Δ⁵-Δ⁴ isomerase: a review. Int J Mol Sci (2013) 0.78
The relationship between dehydroepiandrosterone (DHEA), working memory and distraction--a behavioral and electrophysiological approach. PLoS One (2014) 0.77
The role of endogenous steroid hormones in the generation of T helper 2-mediated autoimmunity in mercuric chloride-treated Brown-Norway rats. Immunology (2000) 0.75
In rats, oral oleoyl-DHEA is rapidly hydrolysed and converted to DHEA-sulphate. BMC Pharmacol (2007) 0.75
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA (1995) 4.45
Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate (1999) 4.12
Isolation of an RNA with the properties of haemoglobin messenger. Nature (1969) 3.53
Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol (1997) 2.58
The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics (1997) 2.55
Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A (1982) 2.38
New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate (1983) 2.29
SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab (2006) 2.25
Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell (1999) 2.17
The impact of family history on early detection of prostate cancer. Nat Med (1995) 2.14
Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys (1997) 2.10
Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads. Mol Endocrinol (1991) 2.07
Somatostatin: abundance of immunoreactive hormone in rat stomach and pancreas. Science (1975) 2.00
Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab (1997) 1.96
Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology (2001) 1.93
Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol (1992) 1.84
The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. Steroids (1997) 1.76
Assignment of the human 3 beta-hydroxysteroid dehydrogenase gene (HSDB3) to the p13 band of chromosome 1. Cytogenet Cell Genet (1989) 1.70
Benefits of combination therapy with flutamide in patients relapsing after castration. Br J Urol (1988) 1.67
Diabetes Screening in Canada (DIASCAN) Study: prevalence of undiagnosed diabetes and glucose intolerance in family physician offices. Diabetes Care (2001) 1.67
Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab (1994) 1.66
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med (1982) 1.65
Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem (1988) 1.60
Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem (2000) 1.59
Localization of oestrogen receptor alpha, oestrogen receptor beta and androgen receptors in the rat reproductive organs. J Endocrinol (2000) 1.57
Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology (1996) 1.56
Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol (2000) 1.54
Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activity. Urology (1997) 1.53
Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril (1994) 1.50
Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med (1992) 1.50
Combined treatment with LHRH agonist and pure antiandrogen in advanced carcinoma of prostate. Lancet (1984) 1.49
Isolation and structure of somatostatin from porcine hypothalami. Biochemistry (1976) 1.46
Is dehydroepiandrosterone a hormone? J Endocrinol (2005) 1.46
Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer (2003) 1.44
The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care (1996) 1.43
Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet (1996) 1.42
Efficacy of essential oil of Ocimum basilicum L. and O. gratissimum L. applied as an insecticidal fumigant and powder to control Callosobruchus maculatus (Fab.) J Stored Prod Res (2001) 1.42
[Currarino syndrome: an association not to be overlooked]. Arch Fr Pediatr (1991) 1.41
Prostate cancer. Lancet (1994) 1.40
Important prognostic value of standardized objective criteria of response in stage D2 prostatic carcinoma. Eur J Cancer Clin Oncol (1988) 1.38
Immunohistochemical localization of beta-lipotropic hormone in the pituitary gland. Endocrinology (1977) 1.38
Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet (1998) 1.35
DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids (1998) 1.35
Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics (1997) 1.31
Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 A resolution. Structure (1995) 1.30
Mortality and life expectancy of Down's syndrome in Denmark. J Ment Defic Res (1986) 1.29
Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release. J Biol Chem (1978) 1.26
Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol (1985) 1.26
Molecular cloning of human type 3 3 alpha-hydroxysteroid dehydrogenase that differs from 20 alpha-hydroxysteroid dehydrogenase by seven amino acids. Biochem Biophys Res Commun (1996) 1.25
Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration. Arch Sex Behav (1988) 1.21
3'-azido-3'-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos (2000) 1.20
Antibody prevalence against haemorrhagic fever viruses in randomized representative Central African populations. Res Virol (1989) 1.18
Characterization of UDP-glucuronosyltransferases active on steroid hormones. J Steroid Biochem Mol Biol (1999) 1.16
Development of the hypothalamic-pituitary-thyroid axis in the neonatal rat. Endocrinology (1975) 1.16
Unique features of the basal cells of human prostate epithelium. Microsc Res Tech (2000) 1.16
Characterization of human 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase gene and its expression in mammalian cells. J Biol Chem (1990) 1.15
Reproducibility, bioinformatic analysis and power of the SAGE method to evaluate changes in transcriptome. Nucleic Acids Res (2005) 1.14
Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology (1999) 1.14
Differential regulation of two uridine diphospho-glucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells. Endocrinology (1997) 1.14
Chromosomal localization, structure, and regulation of the UGT2B17 gene, encoding a C19 steroid metabolizing enzyme. DNA Cell Biol (1997) 1.13
[Slowly developing and clinically benign reticulopathy with extremely malignant histological structure]. Hautarzt (1965) 1.13
In vitro interactions of gastrointestinal hormones on cyclic adenosine 3':5'-monophosphate levels and amylase output in the rat pancreas. Gastroenterology (1975) 1.12
Natural antibodies against three distinct and defined antigens of Plasmodium falciparum in residents of a mesoendemic area in Gabon. Am J Trop Med Hyg (1988) 1.12
Physiological role of somatostatin in the control of growth hormone and thyrotropin secretion. Biochem Biophys Res Commun (1976) 1.12
Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids. J Biol Chem (1996) 1.12
Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. J Steroid Biochem Mol Biol (1992) 1.11
Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate (1995) 1.11
Ocular toxicity of Anandron in patients treated for prostatic cancer. Br J Ophthalmol (1986) 1.10
The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology (1985) 1.10
Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab (1997) 1.10
DHEA and peripheral androgen and estrogen formation: intracinology. Ann N Y Acad Sci (1995) 1.09
Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry (2001) 1.08
Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol (1996) 1.08